Researchers from Exscientia, the Medical University of Vienna, and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences demonstrated the impact of using Exscientia’s AI-supported precision medicine platform to propose which therapy would be most effective for late-stage hematological cancer patients, based on testing drug responses ex vivo in their own tissue samples.
Participants in a prospective, multi-center, randomized, crossover study (NILE – NCT04908254) reported significantly greater adherence to Dayspring treatment, an active compression treatment for lymphedema, in comparison to the use of pneumatic compression pump.
USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has launched a global registration, phase II clinical trial investigating the efficacy of a potential new breast cancer therapy called ARX788.
Ringling College of Art and Design and Moffitt Cancer Center will present an update on new developments from their collaborative INDEX Virtual Reality project to enhance the cancer patient experience and improve the accuracy of MRI-guided Radiation Therapy.
One in seven cancer patients around the world missed out on potentially life-saving operations during COVID-19 lockdowns, a study from the University of Birmingham in the U.K. found.
A study from USC Norris Comprehensive Cancer Center, part of Keck Medicine, showed that while cases of hepatocellular carcinoma have begun slowing in urban communities in the U.S., the incidence of the cancer is rising at a rate of 5.7% annually in rural areas, approaching urban rates.
The Action Collaborative on Preventing Sexual Harassment in Higher Education—part of the National Academies of Science, Engineering, and Medicine—published its first collaborative resource: a Guidance Document on Measuring Sexual Harassment Prevalence Using Campus Climate Surveys.
Researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) showed that chronic physiologic “wear and tear” from stress, known as allostatic load, may be associated with a decreased likelihood of cancer treatment completion and lower overall survival.
Researchers at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and the Mayo Clinic have discovered a way to supercharge molecular cancer treatments to destroy more cancer-causing proteins in cells.
The Lung Cancer Master Protocol public-private partnership—which includes the NCI, the National Clinical Trials Network Cooperative Groups (SWOG, ECOG-ACRIN, Alliance, and NRG), Friends of Cancer Research, and the Foundation for the National Institutes of Health—will study the IL-15 receptor superagonist complex Anktiva (N-803) in the Lung-MAP clinical trial.
